Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DCFPyL PET/CT Clear all
Withdrawn Phase 2Phase 3 Interventional

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

NCT07084909
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
piflufolastat F 18
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 2, 2026, 9:27 AM EDT
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 2, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies

NCT03387514
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

NCT03542773
View directory record Official record
Conditions
Schwannomas, Malignant Tumors
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

NCT03824275
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
18F- DCFPyL PET/CT
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 2, 2026, 9:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT02981368
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 4 Interventional

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

NCT06074510
View directory record Official record
Conditions
Prostate Cancer
Interventions
Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

NCT03173924
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
Interventions
18F-NaF, 18F-DCFPyL, 18F-FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

NCT02523924
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
18F-DCFPyL
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 2, 2026, 9:27 AM EDT
Recruiting Phase 4 Interventional

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NCT06706921
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Interventions
18F-Fluciclovine PET/CT Scan
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 2, 2026, 9:27 AM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Recruiting Phase 2 Interventional

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

NCT04700332
View directory record Official record
Conditions
Prostate Cancer
Interventions
DCFPyL PET/CT
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 2, 2026, 9:27 AM EDT
No Longer Available No phase listed Expanded access

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

NCT03501940
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression, Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Radiation · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 2, 2026, 9:27 AM EDT
Not listed Phase 2 Interventional

PSMA PET Scan and mpMRI for Prostate Cancer Detection

NCT05820724
View directory record Official record
Conditions
Prostate Cancer Diagnosis
Interventions
PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
Diagnostic Test · Other · Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 2, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
18F-DCFPyL, PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

NCT03976843
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Not applicable Interventional Results available

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer

NCT05470699
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Piflufolastat, Positron Emission Tomography
Procedure · Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Completed No phase listed Observational

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

NCT02856100
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F DCFPyL- Radiopharmaceutical
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 2, 2026, 9:27 AM EDT
Completed Early Phase 1 Interventional

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

NCT03232164
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm
Interventions
18F-DCFPyL PET
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 2, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

NCT06322576
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
177Lu-PNT2002
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 2, 2026, 9:27 AM EDT
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 2, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

NCT03585114
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[F-18] DCFPyL, PET/CT imaging
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 2, 2026, 9:27 AM EDT